6:04 p.m. ET, June 11, 2021
Novavax says a version of its vaccine targeting the B.1.351 variant shows positive results in animal studies
From CNN's Jacqueline Howard
Biotechnology company Novavax said Friday that studies in mice, baboons, and humans suggest that a version of its coronavirus vaccine specifically developed to target the B.1.351 variant first identified in South Africa can elicit "strong" immune responses.
That may indicate it protects against both the B.1.351 and the B.1.1.7 variant, first identified in the United Kingdom, the company said.
The studies compared data on the B.1.351-directed vaccine with data on Novavax's original coronavirus vaccine, the company noted, and the vaccines were tested on their own, in combination, and as primers or boosters. The findings published in a preprint paper on the medical server biorxiv.org and the company said the data have been submitted for peer review.
"These data suggest that not only could one booster dose of this variant-directed vaccine potentially provide a robust, protective immune boost after vaccination against the original SARS-CoV-2 virus, but also the potential to provide broad protection against various virus strains if used as a primary vaccine regimen," Dr. Gregory Glenn, president of research and development at Novavax, said in a statement.
"This broad immune coverage is vital to controlling the pandemic as variants of concern continue to emerge worldwide that could jeopardize the protection created through ongoing COVID-19 vaccination efforts," Glenn said.
In the rodent study, mice were immunized with either the B.1.351 or original vaccine alone, in combination, or in a prime-boost series. Novavax announced that whether immunized with any of those options, mice were protected when challenged with live strains of the B.1.1.7 or B.1.351 variants.
In the baboon study, the animals that had been immunized with the original vaccine a year before were boosted with one or two doses of the B.1.351 vaccine. Seven days after a first boost, the baboons exhibited a strong immune response and the results suggest one dose of the B.1.351 vaccine "may be sufficient" for boosting after previous immunizations with vaccines that are based on the original virus strain, the company said.
In the human study, researchers analyzed serum samples collected from 30 people participating in Phase 2 clinical trials of Novavax's original vaccine. The serum samples demonstrated neutralizing capacity against the B.1.1.7 variant, but there was a "modest reduction in neutralizing capacity" against the B.1.351 strain, the company noted, adding that the finding supports the development and production of a B.1.351 vaccine.